Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer.

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer. Clin Transl Oncol. 2018 Jul 26;: Authors: Anido-Herranz U, Fernández-Núñez N, Afonso-Afonso J, Santomé-Couto L, Medina-Colmenero A, Fernández-Calvo O, Lázaro-Quintela M, Vázquez S Abstract Administration of chemotherapy in prostate cancer depends on patient fitness. In unfit patients, physiological impairment determines the optimum treatment. Although no consensus on assessing patient fitness currently exists, this article proposes an algorithm combining the available information for administering chemotherapy, and in particular docetaxel, in unfit patients. It was constructed by reviewing factors that can influence treatment, such as performance status, taxane-related comorbidities and nutritional status. Geriatric scales for prostate cancer patients and alternative treatment regimens for this population are also reviewed. In summary, patients require overall assessment to optimise treatment. Use of docetaxel should be restricted in unfit patients, and other options must be evaluated, because of high toxicity and low efficacy. PMID: 30051212 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Oncol Source Type: research